Figures computed from official regulatory filings — .
Analysttarget 16 USD (+10567%) · consensus 3/5 · 0 buy · 4 hold · 0 sell
Ownershipinsiders 0.62% · institutions 6.64% · short 1.1% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Lyra Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
34 buys27 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Smith W Bradford | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Palasis Maria | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Cavalier Jason | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Palasis Maria | Sell | $5.7K | SEC |
| Cavalier Jason | Sell | $2.6K | SEC |
| PERCEPTIVE ADVISORS LLCtrack record | Sell | $2.3K | SEC |
| PERCEPTIVE ADVISORS LLCtrack record | Sell | $3.6K | SEC |
| PERCEPTIVE ADVISORS LLCtrack record | Sell | $111.5K | SEC |
| PERCEPTIVE ADVISORS LLCtrack record | Sell | $12.5K | SEC |
| PERCEPTIVE ADVISORS LLCtrack record | Sell | $31.9K | SEC |
| PERCEPTIVE ADVISORS LLCtrack record | Sell | $20.6K | SEC |
| EDELMAN JOSEPHtrack record | Sell | $149.7K | SEC |
| EDELMAN JOSEPHtrack record | Sell | $9.5K | SEC |
| EDELMAN JOSEPHtrack record | Sell | $16.8K | SEC |
| EDELMAN JOSEPHtrack record | Sell | $75.5K | SEC |
| EDELMAN JOSEPHtrack record | Sell | $84.3K | SEC |
| EDELMAN JOSEPHtrack record | Sell | $8.5K | SEC |
| Palasis Maria | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Palasis Maria | Sell | $13.9K | SEC |
| Cavalier Jason | Sell | $6.1K | SEC |
| TOBIN JAMES R | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| snyderman nancy lynn MD | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| MERRIFIELD C ANNtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Smith W Bradford | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Cavalier Jason | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |